Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Cybin Inc (CYBN)

Cybin Inc (CYBN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition FinancialNewsMedia - Wed Jan 24, 8:00AM CST

EQNX::TICKER_START (NYSE:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(NASDAQ:ATAI) EQNX::TICKER_END

CYBN.NE : 0.3450 (-2.82%)
MMED.NE : 14.9000 (+9.48%)
CYBN : 0.2561 (-3.32%)
ATAI : 1.2850 (-1.15%)
MNMD : 7.10 (+2.01%)
SEEL : 0.5650 (-2.59%)
CMPS : 6.23 (+4.53%)
Breakthrough Results: Cybin's CYB003 Demonstrates Remarkable Interim Data in Treating Major Depressive Disorder, Achieving Primary Efficacy Milestone and Delivering Prompt Relief from Depression Symptoms with a Single Dose - Comprehensive Topline Data Anticipated by Q4 2023 Newsfile - Wed Nov 1, 2023

- Interim readout shows rapid, robust, and clinically significant reduction of depression symptoms three weeks after a single 12mg dose, with an unprecedented mean -14 point Montgomery-Asberg Depression...

CYBN : 0.2561 (-3.32%)
CYBN.NE : 0.3450 (-2.82%)
Demand for Abuse Deterrent Formulation Technology Skyrocketing as Opiate Abuse is on the Rise PR Newswire - Wed Sep 20, 2023

/PRNewswire/ -- The demand for abuse deterrent formulation technology is projected to grow due to growing misuse of drugs among the people. Growing demand for...

NTRBW : 1.2400 (+74.65%)
CYBN : 0.2561 (-3.32%)
NTRB : 5.75 (-2.38%)
CMND : 1.5200 (-3.80%)
MNMD : 7.10 (+2.01%)
LLY : 892.87 (-1.53%)
Demand for Abuse Deterrent Formulation Technology Skyrocketing as Opiate Abuse is on the Rise FinancialNewsMedia - Wed Sep 20, 2023

EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:CMND),(NASDAQ:MNMD),(NYSE:CYBN),(NYSE:LLY) EQNX::TICKER_END

NTRB : 5.75 (-2.38%)
NTRBW : 1.2400 (+74.65%)
CMND : 1.5200 (-3.80%)
MNMD : 7.10 (+2.01%)
CYBN : 0.2561 (-3.32%)
LLY : 892.87 (-1.53%)
Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031 FinancialNewsMedia - Wed Jul 26, 2023

EQNX::TICKER_START (NYSE:CYBN),NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(OTCQX:NUMIF) EQNX::TICKER_END

CYBN.NE : 0.3450 (-2.82%)
MMED.NE : 14.9000 (+9.48%)
CYBN : 0.2561 (-3.32%)
CMPS : 6.23 (+4.53%)
SEEL : 0.5650 (-2.59%)
MNMD : 7.10 (+2.01%)
NUMIF : 0.0332 (-2.92%)
NUMI.TO : 0.0400 (-11.11%)
Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031 PR Newswire - Wed Jul 26, 2023

/PRNewswire/ -- Psychedelic and hallucinogenic medicines market have been growing consistently over the past several years and are expected to continue to rise...

NUMI.TO : 0.0400 (-11.11%)
CYBN : 0.2561 (-3.32%)
CMPS : 6.23 (+4.53%)
MNMD : 7.10 (+2.01%)
SEEL : 0.5650 (-2.59%)
NUMIF : 0.0332 (-2.92%)
Cybin Announces Phase 2 Cohort 5 Dosing Completion of CYB003 in Major Depressive Disorder Newswire.ca - Mon Jul 24, 2023

/CNW/ - Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) ("Cybin"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by...

CYBN : 0.2561 (-3.32%)
Cybin to Participate at the 26th Annual Milken Institute Global Conference Business Wire - Fri Apr 28, 2023

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative...

CYBN.NE : 0.3450 (-2.82%)
CYBN : 0.2561 (-3.32%)
Cybin Announces EMBARK Open Access, the First Free Online Course Providing Facilitator Training for Psychedelic Therapy Business Wire - Wed Apr 12, 2023

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative...

CYBN.NE : 0.3450 (-2.82%)
CYBN : 0.2561 (-3.32%)
Cybin to Participate in the Oppenheimer 33rd Annual Healthcare Conference Business Wire - Wed Mar 8, 2023

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® is pleased to announce that Doug...

CYBN.NE : 0.3450 (-2.82%)
CYBN : 0.2561 (-3.32%)

Barchart Exclusives

This 'Boring' Copper Miner Is Outfoxing Its Competitors Barchart - 38 minutes ago
Investors underestimating the rate at which Rio Tinto is evolving. Its $15 billion investment into the giant Oyu Tolgoi copper mine in Mongolia gives Rio the potential to catch up to BHP in terms of production – it could produce close to 900,000 tons by the end of the decade, a 50% increase from 2023. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot